跳至主要内容
临床试验/NCT00731562
NCT00731562已完成1 期

Phase 1, Open-Label, Randomized, Single-Dose, Two-Way Crossover Study To Evaluate The Effect Of Food On The Oral Bioavailability Of A Varenicline Controlled Release Formulation In Healthy Adult Smokers

Pfizer1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2008年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Pfizer
入组人数
24
试验地点
1
主要终点
Varenicline area under the curve (AUC) from time of study medication administration to last quantifiable plasma concentration (AUClast) and AUC from time of study medication administration to infinity (AUCinf).

研究概览

简要总结

  1. To estimate the absorption of a single oral dose of a controlled release varenicline tablet under fed and fasted conditions.
  2. To evaluate the pharmacokinetics, safety, and tolerability of a single dose of a varenicline controlled release tablet under fed and fasted conditions.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy male or female adult smokers
  • 18 to 55 years of age

排除标准

  • Sensitivity to varenicline
  • Illegal drug use
  • Pregnant or nursing females

研究组 & 干预措施

Varenicline Controlled Release, Fasted

Experimental

干预措施: Varenicline Tartrate Controlled Release (Drug)

Varenicline Controlled Release, Fed

Experimental

干预措施: Varenicline Tartrate Controlled Release (Drug)

结局指标

主要结局

Varenicline area under the curve (AUC) from time of study medication administration to last quantifiable plasma concentration (AUClast) and AUC from time of study medication administration to infinity (AUCinf).

时间窗: 5 days

Maximum plasma concentration of varenicline

时间窗: 1 day

次要结局

  • Safety measures including adverse events(5 days)

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验